Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Yi Qiu, Mengxi Su, Leyi Liu, Yiqi Tang, Yuan Pan & Jianbo Sun. (2021) Clinical Application of Cytokines in Cancer Immunotherapy. Drug Design, Development and Therapy 15, pages 2269-2287.
Read now
Read now
Alina Sesarman, Dana Muntean, Bianca Abrudan, Lucia Tefas, Bianca Sylvester, Emilia Licarete, Valentin Rauca, Lavinia Luput, Laura Patras, Manuela Banciu, Laurian Vlase & Alina Porfire. (2021) Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin. Journal of Liposome Research 31:1, pages 1-10.
Read now
Read now
Shihong Li, Beth Goins, William T. Phillips & Ande Bao. (2011) Remote-loading labeling of liposomes with 99mTc-BMEDA and its stability evaluation: effects of lipid formulation and pH/chemical gradient. Journal of Liposome Research 21:1, pages 17-27.
Read now
Read now
Mehrdad Hamidi, Pedram Rafiei & Amir Azadi. (2008) Designing PEGylated therapeutic molecules: advantages in ADMET properties. Expert Opinion on Drug Discovery 3:11, pages 1293-1307.
Read now
Read now
Mehrdad Hamidi, Amir Azadi & Pedram Rafiei. (2006) Pharmacokinetic Consequences of Pegylation. Drug Delivery 13:6, pages 399-409.
Read now
Read now
Charles O Noble, Dmitri B Kirpotin, Mark E Hayes, Christoph Mamot, Keelung Hong, John W Park, Christopher C Benz, James D Marks & Daryl C Drummond. (2004) Development of ligand-targeted liposomes for cancer therapy. Expert Opinion on Therapeutic Targets 8:4, pages 335-353.
Read now
Read now
Peter Hau, Joerg Dietrich, Klaus Fabel & Ulrich Bogdahn. (2002) Advances in the therapy of high-grade glioma at relapse: pegylated liposomal doxorubicin. Expert Review of Neurotherapeutics 2:5, pages 609-615.
Read now
Read now
Alberto A. Gabizon. (2001) Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. Cancer Investigation 19:4, pages 424-436.
Read now
Read now
K. Kostarelos, D. Emfietzoglou & M. Stamatelou. (1999) Liposome-Mediated Delivery of Radionuclides to Tumor Models for Cancer Radiotherapy: A Quantitative Analysis. Journal of Liposome Research 9:3, pages 407-424.
Read now
Read now
Gamze Torun Köse, M. Yakup Arica & Vasif Hasirci. (1998) Low-Molecular-Weight Heparin-Conjugated Liposomes with Improved Stability and Hemocompatibility. Drug Delivery 5:4, pages 257-264.
Read now
Read now
Tony L. Whateley. (1996) Literature Alerts. Drug Delivery 3:4, pages 309-320.
Read now
Read now
Articles from other publishers (63)
Daniela Pozzi & Giulio Caracciolo. (2023) Looking Back, Moving Forward: Lipid Nanoparticles as a Promising Frontier in Gene Delivery. ACS Pharmacology & Translational Science 6:11, pages 1561-1573.
Crossref
Crossref
Augusto Amici, Daniela Pozzi, Cristina Marchini & Giulio Caracciolo. (2023) The Transformative Potential of Lipid Nanoparticle–Protein Corona for Next-Generation Vaccines and Therapeutics. Molecular Pharmaceutics 20:11, pages 5247-5253.
Crossref
Crossref
Bwalya A. Witika, Scott K. Matafwali & Pedzisai A. Makoni. 2023. Nanotechnology Principles in Drug Targeting and Diagnosis. Nanotechnology Principles in Drug Targeting and Diagnosis
63
89
.
Tore Skotland, Tore Geir Iversen, Alicia Llorente & Kirsten Sandvig. (2022) Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges. Advanced Drug Delivery Reviews 186, pages 114326.
Crossref
Crossref
Massimiliano Papi, Daniela Pozzi, Valentina Palmieri & Giulio Caracciolo. (2022) Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting. Nano Today 43, pages 101403.
Crossref
Crossref
Violet V. Sheffey, Emily B. Siew, Eden E. L. Tanner & Omolola Eniola‐Adefeso. (2022) PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery. Advanced Healthcare Materials 11:8, pages 2101536.
Crossref
Crossref
Federico Mazur & Rona Chandrawati. (2021) Membrane Fusion Models for Bioapplications. ChemNanoMat 7:3, pages 223-237.
Crossref
Crossref
Marzena Szwed, Maria Lyngaas Torgersen, Remya Valsala Kumari, Sunil Kumar Yadava, Sascha Pust, Tore Geir Iversen, Tore Skotland, Jyotsnendu Giri & Kirsten Sandvig. (2020) Biological response and cytotoxicity induced by lipid nanocapsules. Journal of Nanobiotechnology 18:1.
Crossref
Crossref
Tang Li, Adrian Hawley, Thomas Rades & Ben J. Boyd. (2020) Exposure of liposomes containing nanocrystallised ciprofloxacin to digestive media induces solid-state transformation and altered in vitro drug release. Journal of Controlled Release 323, pages 350-360.
Crossref
Crossref
Carla Garcia-Mazas, Sheila Barrios-Esteban, Noemi Csaba & Marcos Garcia-Fuentes. 2020. Biomaterials for Cancer Therapeutics. Biomaterials for Cancer Therapeutics
365
398
.
Tang Li, Stephen Mudie, David Cipolla, Thomas Rades & Ben J. Boyd. (2018) Solid State Characterization of Ciprofloxacin Liposome Nanocrystals. Molecular Pharmaceutics 16:1, pages 184-194.
Crossref
Crossref
Nuwan Kothalawala, Thilak K. Mudalige, Patrick Sisco & Sean W. Linder. (2018) Novel analytical methods to assess the chemical and physical properties of liposomes. Journal of Chromatography B 1091, pages 14-20.
Crossref
Crossref
Anders Øverbye, Ann Mari Holsæter, Markus Fusser, Nataša Škalko-Basnet, Tore-Geir Iversen, Maria Lyngaas Torgersen, Tonje Sønstevold, Olav Engebraaten, Kjersti Flatmark, Gunhild Mari Mælandsmo, Tore Skotland & Kirsten Sandvig. (2017) Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget 8:44, pages 76921-76934.
Crossref
Crossref
Alberto A. Gabizon, Yogita Patil & Ninh M. La-Beck. (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resistance Updates 29, pages 90-106.
Crossref
Crossref
Kun Zhang, Pei Li, Yaping He, Xiaowan Bo, Xiaolong Li, Dandan Li, Hangrong Chen & Huixiong Xu. (2016) Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF & chemotherapy synergistic tumor treatment. Biomaterials 99, pages 34-46.
Crossref
Crossref
Hua Wang, Ming Xu, Menghua Xiong & Jianjun Cheng. (2015) Reduction-responsive dithiomaleimide-based nanomedicine with high drug loading and FRET-indicated drug release. Chemical Communications 51:23, pages 4807-4810.
Crossref
Crossref
Manashjit Gogoi, Haladhar D Sarma, Dhirendra Bahadur & Rinti Banerjee. (2014) Biphasic magnetic nanoparticles–nanovesicle hybrids for chemotherapy and self-controlled hyperthermia. Nanomedicine 9:7, pages 955-970.
Crossref
Crossref
Haiqing Yin, Han Chang Kang, Kang Moo Huh & You Han Bae. (2014) Effects of cholesterol incorporation on the physicochemical, colloidal, and biological characteristics of pH-sensitive AB2 miktoarm polymer-based polymersomes. Colloids and Surfaces B: Biointerfaces 116, pages 128-137.
Crossref
Crossref
Hilary Shmeeda, Yasmine Amitay, Dina Tzemach, Jenny Gorin & Alberto Gabizon. (2013) Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. Journal of Controlled Release 167:3, pages 265-275.
Crossref
Crossref
Dikla Gutman & Gershon Golomb. (2012) Liposomal alendronate for the treatment of restenosis. Journal of Controlled Release 161:2, pages 619-627.
Crossref
Crossref
Rupa R. Sawant & Vladimir P. Torchilin. (2012) Challenges in Development of Targeted Liposomal Therapeutics. The AAPS Journal 14:2, pages 303-315.
Crossref
Crossref
Daisuke Kami, Shogo Takeda, Yoko Itakura, Satoshi Gojo, Masatoshi Watanabe & Masashi Toyoda. (2011) Application of Magnetic Nanoparticles to Gene Delivery. International Journal of Molecular Sciences 12:6, pages 3705-3722.
Crossref
Crossref
Yasuhiro Matsumura. (2011) Clinical development of nano-DDS. Drug Delivery System 26:1, pages 20-28.
Crossref
Crossref
Shutao Guo & Leaf Huang. (2011) Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy. Journal of Nanomaterials 2011, pages 1-12.
Crossref
Crossref
Yasuhiro MATSUMURA. (2010) Cancer Chemotherapy by DDS. Oleoscience 10:1, pages 25-30.
Crossref
Crossref
Charles O. Noble, Zexiong Guo, Mark E. Hayes, James D. Marks, John W. Park, Christopher C. Benz, Dmitri B. Kirpotin & Daryl C. Drummond. (2009) Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemotherapy and Pharmacology 64:4, pages 741-751.
Crossref
Crossref
Todd O. Pangburn, Matthew A. Petersen, Brett Waybrant, Maroof M. Adil & Efrosini Kokkoli. (2009) Peptide- and Aptamer-Functionalized Nanovectors for Targeted Delivery of Therapeutics. Journal of Biomechanical Engineering 131:7.
Crossref
Crossref
Ken-ichi Ogawara, Keita Un, Ken-ichi Tanaka, Kazutaka Higaki & Toshikiro Kimura. (2009) In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. Journal of Controlled Release 133:1, pages 4-10.
Crossref
Crossref
P. Khare & S. K. Jain. 2009. 13th International Conference on Biomedical Engineering. 13th International Conference on Biomedical Engineering
1455
1458
.
Daryl C. Drummond, Charles O. Noble, Mark E. Hayes, John W. Park & Dmitri B. Kirpotin. (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. Journal of Pharmaceutical Sciences 97:11, pages 4696-4740.
Crossref
Crossref
Marie-Sophie Martina, Claire Wilhelm & Sylviane Lesieur. (2008) The effect of magnetic targeting on the uptake of magnetic-fluid-loaded liposomes by human prostatic adenocarcinoma cells. Biomaterials 29:30, pages 4137-4145.
Crossref
Crossref
Ken-ichi Ogawara, Keita Un, Keiko Minato, Ken-ichi Tanaka, Kazutaka Higaki & Toshikiro Kimura. (2008) Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. International Journal of Pharmaceutics 359:1-2, pages 234-240.
Crossref
Crossref
Melissa D. Howard, Michael Jay, Thomas D. Dziubla & Xiuling Lu. (2008) PEGylation of Nanocarrier Drug Delivery Systems: State of the Art. Journal of Biomedical Nanotechnology 4:2, pages 133-148.
Crossref
Crossref
Marie-Sophie Martina, Valerie Nicolas, Claire Wilhelm, Christine Ménager, Gillian Barratt & Sylviane Lesieur. (2007) The in vitro kinetics of the interactions between PEG-ylated magnetic-fluid-loaded liposomes and macrophages. Biomaterials 28:28, pages 4143-4153.
Crossref
Crossref
Einat Cohen-Sela, Victoria Elazar, Hila Epstein-Barash & Gershon Golomb. 2007. Nanoparticulate Drug Delivery Systems. Nanoparticulate Drug Delivery Systems
235
269
.
T Negishi, F Koizumi, H Uchino, J Kuroda, T Kawaguchi, S Naito & Y Matsumura. (2006) NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. British Journal of Cancer 95:5, pages 601-606.
Crossref
Crossref
Ramakrishna Nallamothu, George C. Wood, Christopher B. Pattillo, Robert C. Scott, Mohammad F. Kiani, Bob M. Moore & Laura A. Thoma. (2006) A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation. AAPS PharmSciTech 7:2, pages E7-E16.
Crossref
Crossref
Alberto A. Gabizon, Dinah Tzemach, Aviva T. Horowitz, Hilary Shmeeda, Jerry Yeh & Samuel Zalipsky. (2006) Reduced Toxicity and Superior Therapeutic Activity of a Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes. Clinical Cancer Research 12:6, pages 1913-1920.
Crossref
Crossref
Robert Jan Veldman, Gerben A. Koning, Albert van Hell, Shuraila Zerp, Stefan R. Vink, Gert Storm, Marcel Verheij & Wim J. van Blitterswijk. (2005)
Coformulated
N
-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin
. Journal of Pharmacology and Experimental Therapeutics 315:2, pages 704-710.
Crossref
Crossref
H Uchino, Y Matsumura, T Negishi, F Koizumi, T Hayashi, T Honda, N Nishiyama, K Kataoka, S Naito & T Kakizoe. (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. British Journal of Cancer 93:6, pages 678-687.
Crossref
Crossref
Daryl C. Drummond, Corina Marx, Zexiong Guo, Gary Scott, Charles Noble, Donghui Wang, Maria Pallavicini, John W. Park, Dmitri B. Kirpotin & Christopher C. Benz. (2005) Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes. Clinical Cancer Research 11:9, pages 3392-3401.
Crossref
Crossref
Thomas L. Andresen, Simon S. Jensen & Kent Jørgensen. (2005) Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Progress in Lipid Research 44:1, pages 68-97.
Crossref
Crossref
Scott L. Kominsky, Mustafa Vali, Dorian Korz, Theodore G. Gabig, Sigmund A. Weitzman, Pedram Argani & Saraswati Sukumar. (2004) Clostridium perfringens Enterotoxin Elicits Rapid and Specific Cytolysis of Breast Carcinoma Cells Mediated through Tight Junction Proteins Claudin 3 and 4. The American Journal of Pathology 164:5, pages 1627-1633.
Crossref
Crossref
Y. Matsumura, M. Gotoh, K. Muro, Y. Yamada, K. Shirao, Y. Shimada, M. Okuwa, S. Matsumoto, Y. Miyata, H. Ohkura, K. Chin, S. Baba, T. Yamao, A. Kannami, Y. Takamatsu, K. Ito & K. Takahashi. (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Annals of Oncology 15:3, pages 517-525.
Crossref
Crossref
Y. Matsumura. 2004. Polymer Drugs in the Clinical Stage. Polymer Drugs in the Clinical Stage
178
194
.
Alberto Gabizon, Hilary Shmeeda & Yechezkel Barenholz. (2003) Pharmacokinetics of Pegylated Liposomal Doxorubicin. Clinical Pharmacokinetics 42:5, pages 419-436.
Crossref
Crossref
Yoshihisa Tsukioka, Yasuhiro Matsumura, Tetsuya Hamaguchi, Hiroyo Koike, Fuminori Moriyasu & Tadao Kakizoe. (2005) Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil). Japanese Journal of Cancer Research 93:10, pages 1145-1153.
Crossref
Crossref
A Manosroi, K Podjanasoonthon & J Manosroi. (2002) Development of novel topical tranexamic acid liposome formulations. International Journal of Pharmaceutics 235:1-2, pages 61-70.
Crossref
Crossref
Miriam Sharpe, Stephanie E. Easthope, Gillian M. Keating & Harriet M. Lamb. (2002) Polyethylene Glycol-Liposomal Doxorubicin. Drugs 62:14, pages 2089-2126.
Crossref
Crossref
Mats Silvander. 2002. Lipid and Polymer-Lipid Systems. Lipid and Polymer-Lipid Systems
35
40
.
Alexander A. Yaroslavov, Oleg Yu. Udalykh, Nickolay S. Melik-Nubarov, Viktor A. Kabanov, Yuri A. Ermakov, Vladimir A. Azov & Fredric M. Menger. (2001) Conventional and Gemini Surfactants Embedded within Bilayer Membranes: Contrasting Behavior. Chemistry - A European Journal 7:22, pages 4835-4843.
Crossref
Crossref
Klaus Fabel, J�rg Dietrich, Peter Hau, Caecilie Wismeth, Beate Winner, Saskia Przywara, Andreas Steinbrecher, Winfried Ullrich & Ulrich Bogdahn. (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92:7, pages 1936-1942.
Crossref
Crossref
M.R. Ranson, S. Cheeseman, S. White & J. Margison. (2001) Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Critical Reviews in Oncology/Hematology 37:2, pages 115-120.
Crossref
Crossref
Daryl C Drummond, Monia Zignani & Jean-Christophe Leroux. (2000) Current status of pH-sensitive liposomes in drug delivery. Progress in Lipid Research 39:5, pages 409-460.
Crossref
Crossref
A Nagayasu, K Uchiyama & H Kiwada. (1999) The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Advanced Drug Delivery Reviews 40:1-2, pages 75-87.
Crossref
Crossref
Alexander T. FlorenceParinya ArunothayanunSandeep KiriMarie-Sophie BernardIjeoma F. Uchegbu. (1999) Some Rheological Properties of Nonionic Surfactant Vesicles and the Determination of Surface Hydration. The Journal of Physical Chemistry B 103:11, pages 1995-2000.
Crossref
Crossref
Mats Silvander, Markus Johnsson & Katarina Edwards. (1998) Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum. Chemistry and Physics of Lipids 97:1, pages 15-26.
Crossref
Crossref
Dilair F Baban & Leonard W Seymour. (1998) Control of tumour vascular permeability. Advanced Drug Delivery Reviews 34:1, pages 109-119.
Crossref
Crossref
Ijeoma Uchegbu. (1998) The biodistribution of novel 200-nm palmitoyl muramic acid vesicles. International Journal of Pharmaceutics 162:1-2, pages 19-27.
Crossref
Crossref
DORIT GOREN & ALBERTO GABIZON. 1998. Medical Applications of Liposomes. Medical Applications of Liposomes
259
274
.
Dorit Goren, Samuel Zalipsky, Aviva T. Horowitz & Alberto Gabizon. 1998. Targeting of Drugs 6. Targeting of Drugs 6
77
85
.
D. Polo, I. Haro, M. A. Alsina & F. Reig. (1997) Physicochemical Characterization of Poly(ethylene glycol)-Coated Liposomes Loaded with Doxorubicin. Langmuir 13:15, pages 3953-3958.
Crossref
Crossref
Alberto Gabizon, Dorit Goren, Aviva T. Horowitz, Dinah Tzemach, Alexander Lossos & Tali Siegal. (1997) Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Advanced Drug Delivery Reviews 24:2-3, pages 337-344.
Crossref
Crossref